Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.78 |
| ▸ | DDX3X | O00571 | 7/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.60 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.60 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.60 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.60 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11899366 | 0.87 | DDX3X (1.00) | MEN1KMT2ADDX3XMAPTLMNA | |
| SCHEMBL11899368 | 0.87 | DDX3X (1.00) | MEN1KMT2ADDX3XMAPTLMNA | |
| SCHEMBL11899367 | 0.87 | DDX3X (1.00) | MEN1KMT2ADDX3XMAPTLMNA | |
| SCHEMBL12008750 | 0.86 | DDX3X (0.80) | MEN1KMT2ADDX3XMAPTLMNA | |
| SCHEMBL11913686 | 0.86 | DDX3X (0.80) | MEN1KMT2ADDX3XMAPTLMNA | |
| SCHEMBL17319539 | 0.85 | DDX3X (0.83) | MEN1KMT2ADDX3XALDH1A1SMN1; SMN2 | |
| SCHEMBL1655416 | 0.83 | DDX3X (1.00) | MEN1KMT2ADDX3XMAPTLMNA | |
| SCHEMBL1655419 | 0.83 | DDX3X (1.00) | MEN1KMT2ADDX3XMAPTLMNA | |
| SCHEMBL1655418 | 0.83 | DDX3X (1.00) | MEN1KMT2ADDX3XMAPTLMNA | |
| SCHEMBL12008955 | 0.83 | MEN1 (0.76) | MEN1KMT2ADDX3XMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206412-B2 | Thioxothiazolidine inhibitors | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2015-12-08 | — | — | US | disclosed |
| US-20120202814-A1 | COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF | UNIVERSITÀ DEGLI STUDI DI SIENA (IT) | 2012-08-09 | — | — | US | disclosed |
| US-20120202814-A1 | COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF | UNIVERSITÀ DEGLI STUDI DI SIENA (IT) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202814-A1 | COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF | DDX3X, DDX21, DDX39B | MEN1 1855/4885KMT2A 2610/4885DDX3X 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.